1'-{[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-{3-[(methylsulfonyl)amino]-propyl}-1H-pyrrol-2-yl]carbonyl}-1,4'-bipiperidine-4'-carboxamide | 1026665-95-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1'-{[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-{3-[(methylsulfonyl)amino]-propyl}-1H-pyrrol-2-yl]carbonyl}-1,4'-bipiperidine-4'-carboxamide
• 英文别名: 1'-{[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-{3-[(methylsulfonyl)amino]propyl}-1H-pyrrol-2-yl]carbonyl}-1,4'-bipiperidine-4'-carboxamide；1-[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1-[3-(methanesulfonamido)propyl]pyrrole-2-carbonyl]-4-piperidin-1-ylpiperidine-4-carboxamide
• CAS: 1026665-95-1
• 化学式: C₃₂H₃₈Cl₃N₅O₄S
• 分子量: 695.11
• InChiKey: LSAFCWIWFVDRJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  45
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1-(3-methanesulfonylamino-propyl)-1H-pyrrole-2-carboxylic acid 、 (1,4’-二哌啶)-4’-甲酰胺 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1'-{[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-{3-[(methylsulfonyl)amino]-propyl}-1H-pyrrol-2-yl]carbonyl}-1,4'-bipiperidine-4'-carboxamide
  参考文献：
  名称：

  Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif

  摘要：

  A new series of 2,3-diarylpyrroles have been prepared and evaluated as CB1 antagonists. Modulation of the topological polar surface area allowed the identification of high affinity peripherally-restricted CB1 antagonists. Compound 11, obtained after further optimization of the metabolic profile displayed very low brain penetration, yet was able to reverse CP55940-induced gastrointestinal transit inhibition following oral administration. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.017

文献信息

• PYRROLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Barth Francis

  公开号：US20090281116A1

  公开（公告）日：2009-11-12

  The invention relates to compounds having the formula (I): Wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 9 and A-R 9 are as defined herein. Also disclosed are the preparative methods for the compounds of formula (I) and their use in therapy.

  这项发明涉及具有以下结构式（I）的化合物：其中R1、R2、R3、R4、R5、R6、R7和R9以及A-R9如本文所定义。还披露了结构式（I）化合物的制备方法以及它们在治疗中的用途。
• DERIVES DE PYRROLE, LEUR PREPARATION ET LEUR UTILISATION EN THERAPEUTIQUE.
  申请人：SANOFI

  公开号：EP2094656B1

  公开（公告）日：2011-08-17
• US8044072B2
  申请人：——

  公开号：US8044072B2

  公开（公告）日：2011-10-25
• Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif
  作者：Laurent Hortala、Murielle Rinaldi-Carmona、Christian Congy、Laurent Boulu、Freddy Sadoun、Gérard Fabre、Olivier Finance、Francis Barth

  DOI：10.1016/j.bmcl.2010.06.017

  日期：2010.8

  A new series of 2,3-diarylpyrroles have been prepared and evaluated as CB1 antagonists. Modulation of the topological polar surface area allowed the identification of high affinity peripherally-restricted CB1 antagonists. Compound 11, obtained after further optimization of the metabolic profile displayed very low brain penetration, yet was able to reverse CP55940-induced gastrointestinal transit inhibition following oral administration. (C) 2010 Elsevier Ltd. All rights reserved.